Should every transplant eligible NDMM patient receive a transplant?

Bookmark and Share
Published: 14 Sep 2021
Views: 930
Rating:
Save
Prof Morie Gertz - Mayo Clinic, Rochester, USA

Dr Morie Gertz speaks to ecancer about his talk at IMW 2021.

He addresses the topic of whether every transplant eligible NDMM patient should receive a transplant or not.

Initially, he explains the background behind this discussion. He then talks about how the goal of therapy is MRD negativity.

Dr Gertz quotes data from studies where combinations of non-cross agents are used and the role of stem cell transfer declines. He says that the non-transplant regiment has shown minimum MRD.

He concludes by explaining why through multiple novel agents minimum negativity can be achieved.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

New MM patients with high levels of circulating tumour cells distinguished by in...
Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands
New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )
21 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )
31 Aug 2021
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...
Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )
19 Jul 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )
11 Jun 2021
Clinically sufficient vitamin D levels at breast cancer diagnosis and survival o...
Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021